Clinical-therapeutic study of dementia in people with down syndrome and the effectiveness of donepezil in this population;Estudio clinicoterapéutico de la demencia en las personas con síndrome de Down y eficacia del donepecilo en esta población

Revista de Neurologia

Volumn 41, Issue 3, 2005, Pages 129-136

  Boada Rovira, M ^a,b   Hernández Ruiz, Isabel ^a   Badenas Homiar, S ^a   Buendia Torras M ^a   Tarraga Mestre L ^a  

^a Institut Catala de Neurociencies Aplicades   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Donepezil; Down syndrome; Efficacy; Progressive dementia syndrome; Safety

Indexed keywords

DONEPEZIL; CHOLINESTERASE INHIBITOR; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

ADULT; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; DIARRHEA; DISABILITY; DISEASE COURSE; DOWN SYNDROME; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; HEALTH CARE PERSONNEL; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PATIENT SELECTION; PILOT STUDY; PUBLICATION; SOCIAL ASPECT; TREATMENT DURATION; TREATMENT RESPONSE; VALIDATION PROCESS; AGED; AGING; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DEMENTIA; DOWN SYNDROME; HUMANS; INDANS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PIPERIDINES;

EID: 33644804252     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4103.2004536     Document Type: Article

References (26)

1. Penrose L. The incidence of mongolism in the general population. J Ment Sci 1949; 95: 658-88.
2. Carter G, Jancar J. Mortality in the mentally handicapped: a 50 year survey at the Stoke Park group of hospitals (1930-1980). J Ment Defic Res 1983; 27: 143-56.
3. Strauss D, Eyman RK. Mortality of people with mental retardation in California with and without Down syndrome, 1986-1991. Am J Ment Retard 1996; 100: 643-53.
4. Stoltzner SE, Grenfell TJ, Mori C, Wisniewski KE, Wisniewski TM, et al. Temporal accrual of complement proteins in amyloid plaques Down's syndrome with Alzheimer's disease. Am J Pathol 2000; 156: 489-99.
5. Head E, Azizeh BY, Lott IT, Tenner AJ, Cotman CW, Cribbs DH. Complement association with neurons and beta-amyloid deposition in the brains of aged individuals with Down syndrome. Neurobiol Dis 2001; 8: 252-65.
6. Schapiro MB, Haxby JV, Grady CL. Nature of mental retardation and dementia in Down syndrome: study with PET, CT and neuropsychology. Neurobiol Aging 1992; 13: 723-34.
7. Kesslak JP, Nagata SF, Lott I, Nalcioglu O. Magnetic resonance imaging analysis of age-related changes in the brains of individuals with Down's syndrome. Neurology 1994; 44: 1039-45.
8. Rubinsztein DC, Hon J, Stevens F, Pyrah I, Tysoe C, Huppert FA, et al. Apo E genotype and risk of dementia in Down's syndrome. Am J Med Genet 1999; 88: 344-7.
9. Kishnani PS, Sullivan JA, Walter BK, Spiridigliozzi GA, Doraiswamy PM, Krishnan KR. Cholinergic therapy for Down's syndrome. Lancet 1999; 353: 1064-5.
10. Hemingway-Eltomey JM, Lerner AJ. Adverse effects of donepezil in treating Alzheimer's disease associated with Down's syndrome. Am J Psychiatry 1999; 156: 1470.
11. Prasher VP, Huxley A, Haque MS, Down syndrome Ageing Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease. Int J Geriatr Psychiatry 2002; 17:270-8.
12. Lott IT, Osann K, Doran E, Nelson L. Down syndrome and Alzheimer disease: response to donepezil. Arch Neurol 2002; 59: 1133-6.
13. Gedye A. Dementia scale for Down syndrome manual. Vancouver: Gedye Research & Consulting; 1995.
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of NINCDS-ADRDA Work Group. Neurology 1984; 34: 939-44.
15. Visser FE, Aldenkamp AP, Van Huffelen AC. Early signs of dementia checklist. Am J Ment Retard 1997; 101: 400-12.
16. Evenhuis H, Kengen MMF, Eurlings HAL. Dementia questionnaire for mentally retarded persons. Zwammerdam: Hooge Burch; 1990.
17. Evenhuis HM. Evaluation of a screening instrument for dementia in ageing mentally retarded persons. J Intellect Disabil Res 1992; 36: 337-47.
18. Evenhuis HM. Further evaluation of the dementia questionnaire for persons with mental retardation (DMR). J Intellect Disabil Res 1996; 40: 369-73.
19. Prasher VP. Dementia questionnaire for person with mental retardation (DMR): modified criteria for adults with Down syndrome. J Appl Res Intellect Disabil 1997; 10: 54-60.
20. Nihira K, Leland H, Lambert N. Adaptive behavior scale-residential and community (ABS-RC:2). American Association on Mental Retardation. Austin, TX: Pro-Ed; 1993.
21. Senatore V, Matson JL, Kazdin AE. An inventory to assess psychopathology of mentally retarded adults. Am J Ment Defic 1985; 89: 459-66.
22. Aman MG, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985; 89: 485-91.
23. Zarit SH, Reever K, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist 1980; 20: 649-55.
24. Johnson N, Fahey C, Chicoine B, Chong G, Gitelman D. Effects of donepezil on cognitive functioning in Down syndrome. Am J Ment Retard 2003; 108: 367-72.
25. Kishnani PS, Spiridigliozzi GA, Heller JH, Sullivan JA, Doraiswamy PM, Krishnan KR. Donepezil for Down's syndrome. Am J Psychiatry 2001; 158: 143.
26. Prasher VP, Adams C, Holder R, Down Syndrome Research Group. Long term safety and efficacy of donepezil in the treatment of dementia in Alzheimer's disease in adults with Down syndrome: open label study. Int J Geriatr Psychiatry 2003; 18: 549-51.